Read on Twitter
MediWound-PATH TO 5X
Mcap: $110MM
Cash: $22.5M(burn rate ~9M/year).
My thesis: Recent events show that re-rating is imminent yet Mr. Market is not connecting the dots, lets help him out.
$MDWD has two best-in-class products:
NexoBrid(TAM: 200MM)
*sold internationally for burns
Mcap: $110MM
Cash: $22.5M(burn rate ~9M/year).
My thesis: Recent events show that re-rating is imminent yet Mr. Market is not connecting the dots, lets help him out.
$MDWD has two best-in-class products:
NexoBrid(TAM: 200MM)
*sold internationally for burns
, it is made of enzyme from pineapples so its very safe.
Despite being used around the world since the 1980's it is not yet approved by the FDA; so why do I have no doubt it will get approve by the FDA on its review in June?
1-The product has been used successfully
Despite being used around the world since the 1980's it is not yet approved by the FDA; so why do I have no doubt it will get approve by the FDA on its review in June?
1-The product has been used successfully
since the 1980's around the world during that time it passed around eight phase II/III trials.
2-FDA granted BARDA, which is a U.S. government agency approval to stockpile on NexoBrid
3-BARDA actually sponsored the entire approval process with the FDA...
2-FDA granted BARDA, which is a U.S. government agency approval to stockpile on NexoBrid
3-BARDA actually sponsored the entire approval process with the FDA...
for the tune of tens of millions of $.
4-FDA decided to not conduct an advisory committee meeting to review NexoBrid's BLA-very bullish.
I give an FDA approval probability of 95%, once approved $MDWD will receive a $7.5M milestone and up to $125M in sales-based payments from
4-FDA decided to not conduct an advisory committee meeting to review NexoBrid's BLA-very bullish.
I give an FDA approval probability of 95%, once approved $MDWD will receive a $7.5M milestone and up to $125M in sales-based payments from
partner $VCEL which mentioned in its recent investor day how excited it is to start marketing the product and how it has set an entire sales team just for that. The product doesn't really have any direct competition and $VCEL has relationship with most of NexoBrid target clients
Now lets move to the next product, which if approved could make $MDWD a 7X stock and just like NexoBrid also here the market is ignoring the positive omens The second product is:
EscharEx(TAM: $1B-plus)
Made from the same enzymes as the soon to be FDA approved NexoBird
EscharEx(TAM: $1B-plus)
Made from the same enzymes as the soon to be FDA approved NexoBird
EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds.
I have conviction regarding EscharEx’s efficacy thanks to its established mechanism and solid clinical results
to date. I want to touch on a few key points so lets start
I have conviction regarding EscharEx’s efficacy thanks to its established mechanism and solid clinical results
to date. I want to touch on a few key points so lets start
1-The problem this product is trying to solve is similar to the soon to be FDA approved NexoBrid.
2-On December, in an event that went unacknowledged by the market EscharEx showed superiority vs Santyl in a hard-to-heal wounds model in pigs . The trial was conducted in
2-On December, in an event that went unacknowledged by the market EscharEx showed superiority vs Santyl in a hard-to-heal wounds model in pigs . The trial was conducted in
collaboration with a U.S. research center. Santyl
is the only FDA approved enzymatic debridement agent with a monopoly status and 300MM of sales. More news about this study will come later this year at a peer-reviewed journal sometime in 1H’21.
3-Due to this bullish trial
is the only FDA approved enzymatic debridement agent with a monopoly status and 300MM of sales. More news about this study will come later this year at a peer-reviewed journal sometime in 1H’21.
3-Due to this bullish trial
$MDWD reduced the planned patient enrollment target in its Phase II/III U.S. trial of EscharEx in venous leg ulcers.
4-The company is conducting other studies of potential use of EscharEx that should see light in 2021.
4-The company is conducting other studies of potential use of EscharEx that should see light in 2021.
Summary:
1) NexoBrid approval by the FDA is a done deal in my view and will lead to re-rating.
2) All the recent news from EscharEx are not reflected in the price.
3) 2021 holds countless catalysts for EscharEx, based on the data we have I expect them to be very positive.
1) NexoBrid approval by the FDA is a done deal in my view and will lead to re-rating.
2) All the recent news from EscharEx are not reflected in the price.
3) 2021 holds countless catalysts for EscharEx, based on the data we have I expect them to be very positive.
